Skip to main content
. 2024 Jun 24;14:1361420. doi: 10.3389/fonc.2024.1361420

Figure 2.

Figure 2

Estimated Kaplan-Meier and the impact of age for patients with advanced intrahepatic cholangiocarcinoma. Cutoff points were ≥ 70 years old (N=14), and < 70 years old (N=21). Two-year survivals were similar, >24 months for both subsets. Survival was calculated from the first day of treatment with GFLIO. At the time of progression, docetaxel/mitomycin C were added, and then subsequently cetuximab and then bevacizumab.